Topic: Csl

CSL Seqirus in North Carolina is working with the U.S. government to manufacture bird flu antigens that can be converted into finished doses. The hosts discuss the financial incentives for pharmaceutical companies to secure government contracts for pandemic response. They mention "Triangle Pharmaceuticals" as a potential player in the burgeoning bird flu industrial complex.

The FDA has approved Provenge, a $93,000 treatment for prostate cancer labeled as a "vaccine," despite it being a therapeutic injection. Meanwhile, in Western Australia, the swine flu vaccine has been linked to severe illness and deaths in children under five. The manufacturer, CSL Limited, maintains that the vaccine is safe despite these reports.

Health authorities in Australia suspended swine flu vaccinations for children under five after reports of convulsions and at least one death. The hosts also discuss a new "deadly fungus" strain, Cryptococcus gattii, spreading in the Pacific Northwest. They predict that the World Health Organization will use this fungus outbreak to justify the development of new, mandatory vaccines.

Human trials for a swine flu vaccine have commenced in Australia at the Royal Adelaide Hospital, involving hundreds of adults and children. CSL Limited is conducting the tests, which include double-dose injections for infants as young as six months to determine efficacy before a planned mass rollout.